Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
NCT06333990

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

Led by Foundation for Advancing Veterans' Health Research · Updated on 2025-07-11

146

Participants Needed

2

Research Sites

203 weeks

Total Duration

On this page

Sponsors

F

Foundation for Advancing Veterans' Health Research

Lead Sponsor

T

The University of Texas Health Science Center at San Antonio

Collaborating Sponsor

AI-Summary

What this Trial Is About

A two site, 2-arm, Phase III randomized pragmatic clinical trial evaluating the effectiveness of quetiapine monotherapy in comparison to Treatment As Usual (TAU) medication management for symptoms experienced by veterans receiving rehabilitation therapy for mild traumatic brain injury (mTBI) and comorbid symptoms of posttraumatic stress disorder (PTSD).

CONDITIONS

Official Title

Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female veterans seeking treatment for mild traumatic brain injury (mTBI), aged 18-65 years
  • Diagnosed with mTBI and experiencing post-concussive symptoms reported on the Neurobehavioral Symptom Inventory (NSI), with at least six months since injury
  • Stable (no dose changes for over 1 month) on at least three CNS-active psychotropic medications for symptom relief or psychiatric treatment
  • Posttraumatic symptoms with PTSD Checklist for DSM-5 (PCL-5) score of 25 or higher
Not Eligible

You will not qualify if you...

  • Moderate or severe traumatic brain injury (TBI) or major neurocognitive disorder (dementia)
  • Diagnosis of schizophrenia, bipolar disorder, schizoaffective disorder, or requiring inpatient hospitalization currently or within past 6 months
  • Use of any antipsychotics or prohibited medications within the past month
  • Known intolerance to quetiapine or unstable heart, lung, liver, kidney, blood, or endocrine conditions; diabetes; severe sleep apnea; or seizure disorder
  • Severe substance use disorder requiring medication treatment, detoxification, or hospitalization within 6 months
  • Suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (CSSRS) in past 3 months or recent suicidal or homicidal behavior
  • History of cardiac arrhythmia or QTc interval of 470 milliseconds or higher
  • Pregnant or lactating women or women of child-bearing potential not using reliable contraception

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

New Mexico VA Healthcare System

Albuquerque, New Mexico, United States, 87108

Actively Recruiting

2

South Texas Veterans Healthcare System

San Antonio, Texas, United States, 78229

Actively Recruiting

Loading map...

Research Team

M

Muhammad R Baig, MD

CONTACT

L

Lizette Aviles, BS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here